Mortality patterns in hypertension

Journal of Hypertension

Volumn 29, Issue SUPPL. 1, 2011, Pages

  Arima, Hisatomi ^a   Barzi, Federica ^a   Chalmers, John ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Blood pressure; Blood pressure lowering; Cardiovascular disease; Hypertension; Mortality patterns

Indexed keywords

SODIUM;

AGING; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISABILITY; DISEASE ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SODIUM INTAKE; STROKE;

EID: 83655196778     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/01.hjh.0000410246.59221.b1     Document Type: Review

References (26)

1. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009.
2. Murray C, Lopez A. The Global Burden of Disease. Cambridge: Harvard School of Public Health; 1996.
3. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-577.
4. World Health Organization. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004.
5. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
6. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens 2003;21:707-716.
7. Lawes CM, Vander Hoorn S, Rodgers A. for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-1518. (Pubitemid 351626187)
8. World Health Organization. Preventing chronic disease: a vital investment. Geneva: World Health Organization; 2005.
9. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-2398. (Pubitemid 46883773)
10. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3: e442.
11. Woodward M, Barzi F, Martiniuk A, Fang X, Gu DF, Imai Y, et al. Cohort profile: the Asia Pacific Cohort Studies Collaboration. Int J Epidemiol 2006;35:1412-1416. (Pubitemid 46178914)
12. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-840.
13. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood pressure lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
14. Arima H, Anderson C, Omae T, Liu L, Tzourio C, Woodward M, et al. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. J Hypertens 2010;28:395-400.
15. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952. (Pubitemid 39208455)
16. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112-123.
17. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
19. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19. (Pubitemid 38293521)
20. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005;23:1575-1581. (Pubitemid 41104830)
21. World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.
22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Managementof Arterial Hypertensionofthe European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
23. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123: e18-e209.
24. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med 2004;1: e27.
25. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
26. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.